88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement ... 2026-06-22T Health Care/Hospital Medical/Pharmaceuticals
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth ... 2026-06-22T Cosmetics & Personal Care Health Care/Hospital Household/Consumer/Cosmetics Medical/Pharmaceuticals
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth ... 2026-06-22T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors SHANGHAI , June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors SHANGHAI , June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell — The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders CAMBRIDGE, Mass. , June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK ), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, ... 2026-06-22T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved